Skip Navigation Linksnewsroom

New to I'm In? Sign-up here.

Welcome, . Sign Out

 Content Editor ‭[1]‬

Newsroom

  • February 1, 2015

    Diversity in Clinical Trials

    A doctor and a breast cancer survivor share their views on why ethnic diversity in clincial trials is so important.

    Read Mo​​​re
  • January 6, 2015

    How Can We Encourage Participation in Clinical Trials?

    Failed clinical trials come at a huge cost to their pharmaceutical sponsors. Many trial sites fail to enroll more than a single patient—up to 60% of oncology trials, according to Covance, for example. Yet they estimate it costs a sponsor $50,000 for a site start-up, with a loss of almost $2 billion between 2006-2010 from non-performing sites.

    Read Mo​​​re
  • January 5, 2015

    ‘I’m In’ Campaign and FDA Recommendations Look to Boost Diversity in C​linical Testing

    Hispanics are most disproportionately affected by asthma, cancer, and heart disease, and scientists are asking why. What is clear is that few Hispanics participate in the clinical trials that test drugs to treat these diseases and others. Overall, just 1 percent of clinical trial volunteers are Hispanic. And the underrepresentation is true across all ethnic and racial minorities.

    Read Mo​​​re
  • ​December 25, 2014

    Texas researchers target aggressive breast cancer with grants

    Cancer research can feel like walking around in a dark room, trying to find a light switch, Rong Li, a professor of molecular medicine at the University of Texas Health Science Center, said recently.

    Read Mo​​​re
  • ​November 17, 2014

    New Study IDs Key Methods To Boost Clinical Trial Awareness, Diversity

    Researchers at The University of Texas Health Science Center at San Antonio have found a new method to increase the diversity of study populations in clinical trials, in particular for Latinos who participate in disproportionately low numbers in cancer clinical trials in the United States.

    Read Mo​​​re
  • ​October 31, 2014

    FSU Researchers Seek Minority Participants For Diabetes Study

    It could be that it takes two apples per day to keep the doctor away. Florida State University researchers are using a clinical trial to look at how eating apples affects Type 2 diabetes. It’s a disease disproportionately affecting minorities. So the Tallahassee team is working to increase ethnic diversity among its participants.

    Read Mo​​​re
  • ​October 20, 2014

    Cancer survivor advocates for breast cancer trials in black community


    Averl Anderson didn’t know cancer was a part of her family history. It wasn’t until later, after she was diagnosed with an aggressive form of breast cancer and when a niece also received the diagnosis that Anderson realized how devastating the illness can be.

    Read Mo​​​re
  • ​October 10, 2014

    Averl Anderson – I’m In


    “Women suffer in silence sometimes,” says Averl Anderson with such calm and nonchalance. You​ don’t have to see her face or hear the smile that reigns supreme in her voice to understand she speaks from experience. A proud woman of faith and minister at Great Emmanuel Temple in Buffalo, New York, Averl still can’t find the words to describe the way she felt when she learned she had triple negative, stage three breast cancer.

    Read Mo​​​re
  • ​September 19, 2014

    Hispanic Heritage Month: The Changing Face of Health Care

    September 15 marks the beginning of Hispanic Heritage Month, a time to pay tribute to the generations of Hispanics who have enriched America’s history. It’s also an important time to consider how this community can be further empowered to make important contributions, particularly in the future of health care.

    Read Mo​​​re
  • ​September 16, 2014

    Medical Research: Missing Patients

    It is widely known that racial and ethnic minorities in the United States have higher rates of diseases such as asthma and cancer, and receive worse care. Compared with white people with similar conditions, minority individuals get fewer heart bypasses and influenza vaccinations.

    Read Mo​​​re
  • ​August 22, 2014

    Recruiting patients for NHS trials – barriers and solutions

    Recruitment is often cited as one of the most difficult and potentially time-consuming tasks in the complex trial management process. But it's not just a case of sheer volume – it sounds obvio​us, but trials should reflect as closely as possible the profile of those who will be receiving any successful treatment.

    Read Mo​​​re
  • ​August 15, 2014

    Hispanos participan muy poco en estudios clínicos

    Los hispanos son el grupo que menos participa en los estudios clínicos en Estados Unidos pese a que en enfermedades como la diabetes lideran la tasa de afectados. Por lo que campañas instan a esta población a una mayor colaboración con las investigaciones.

    Read Mo​​​re
  • ​July 16, 2014

    Will Black People Ever Trust Clinical Trials?

    In order to discover vaccines and treatments that better protect African-Americans, we need to increase our participation in biomedical research as clinical trials subjects, investigators, and on research oversight committees.

    Read Mo​​​re
  • ​June 24, 2014

    Encouraging African American participation in clinical trials is key to curing Alzheimer’s

    The June 20 news article “Large Alzheimer’s study hits a recruitment roadblock ” highlighted the difficulty of recruiting candidates for Alz­heimer’s clinical trials, a critical factor in finding a cure. The issue is even more pressing for African Americans, who are two to three times more likely to develop Alzheimer’s than white Americans. Research shows minorities in the United States live sicker and die younger but are more reluctant to participate in clinical research. African Americans make up more than 13 percent of the population but only 5 percent of clinical trials participants. That percentage is even lower for older African Americans.

    Read Mo​​​re
  • ​June 12, 2014

    Diabetes Researchers Say New CDC Data Does Not Show True Impact of Diabetes Among AANHPI

    This Tuesday, the Centers for Disease Control and Prevention (CDC) released the 2014 National Diabetes Statistics Report (formerly referred to as the National Diabetes Fact Sheet), intended to provide up-to-date scientific data and statistics on diabetes and its burden in the United States. The data released from the CDC underscored the growing epidemic of diabetes in the U.S. and how this disproportionately affects non-White segments of the population.

    Read Mo​​​re
  • ​May 20, 2014

    Racial diversity crucial to trials of drugs, treatments

    As a nurse practitioner, Phyllis Howard understands the value of clinical trials in testing new drugs or treatment protocols. But as an African American woman, she was leery about the idea of being a test subject. "I considered it being experimented on," said Howard, 56, of her initial reaction to a suggestion by her UCSF oncologist that she enroll in a clinical trial shortly after her 2009 breast cancer diagnosis.

    Read Mo​​​re
  • ​May 15, 2014

    To the Editor

    In addressing gender bias in biomedical and clinical research, it’s also important to close gaps in clinical trial participation among minorities to understand how different segments of the population respond to various treatments. When asked if they or someone in their family had ever participated in a trial, only 17 percent of Hispanics, 15 percent of African-Americans and 11 percent of Asian-Americans said yes in polling commissioned by Research!America, a nonprofit advocacy alliance.

    Read Mo​​​re
  • ​May 2, 2014

    Virginia supporting diversity in clinical trials

    Virginia is supporting a national effort to encourage greater diversity of volunteers in clinical trials. Gov. Terry McAuliffe this week announced the state’s support for the “I’m In” campaign launched by the Pharmaceutical Research and Manufacturers of America and the National Minority Quality Forum.

    Read Mo​​​re
  • ​April 29, 2014

    Governor Terry McAuliffe Announces Virginia is “All In”

    Governor McAuliffe today announced Virginia’s support for the “I’m In” campaign to encourage grea​ter diversity of volunteers in clinical trials.

    Read Mo​​​re
  • ​April 19, 2014

    I'm In Campaign

    Asian Americans and Pacific Islanders face unique health disparities, but not enough a​re participating in clinical trials that help find better treatments and fight disease. To increase diversity in clinical trials, the “I’m In” campaign launched in March to target AAPI, African American and Hispanic communities.

    Read Mo​​​re
  • ​April 6, 2014

    How medical research is failing minorities 

    Minorities are getting the short end of the stick when it comes to medical research, and it may have a drastic ​​impact on the health of Hispanics, Asians, African Americans and other minorities in the future.

    Read Mo​​​re
  • ​March 30, 2014

    Medical profession falls short in recruiting minorities for research, study says

    A new UC Davis study published by the American Cancer Society found that of the 10,000 clinical trials funded by the National Institutes of Health since 1997, only about 150 focused on a particular ethnic or minority population.

    Read Mo​​​re
  • ​March​ 28, 2014

    I'm In: National​​ Campaign Urges African American Participation in Clinical Trials 

    On Wednesday, March 12, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Minority Quality Forum announced a groundbreaking campaign to increase diversity in clinical trials, and ultimately change the landscape of medical progress in this country. Appropriately named, “I’m In,” the campaign addresses the disparity among minority groups represented in clinical trials, and highlights the many benefits in participating.​

    Read Mo​​​re
  • ​March 12​, 2014

    National​​ Campaign Launched to Increase Diversity in Clinical Trials 

    A new initiative was launched on Wednesday to boost the participation of minorities in clinical trials and correct a long-standing imbalance that experts say has hurt medical treatment for some underrepresented groups.​

    The national campaign, created by the Pharmaceutical Research and Manufacturers of America (PhRMA) partnering with the health care group the National Minority Quality Forum, is called "I'm in" and was presented at a press conference.

    Read Mo​​​re
  • ​March 16, 2014

    Nationwide effort aims for more diversity in clinical drug trials

    Thousands of volunteers participate in clinical trials across the United States each year, all hoping that the experimental treatment will help ease their pain or cure their disease. While the trials target a host of different ailments, there is one thing most of those patients have in common. The vast majority are white, a well-documented fact that health care experts say has changed little over the years and is cause for alarm.

    Read Mo​​​re
  • Diversity in clinical trials gets push in national campaign

    Despite the mandate in section 907 of the FDA Safety and Innovation Act of 2012 (FDASIA) that the FDA seek the inclusion of demographic “subgroups” in clinical trials, both the agency and drugmakers have struggled to improve participation rates among historically underrepresented populations, especially African Americans and Hispanics. Now, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Minority Quality Forum are going directly to the public with a campaign called “I’m In” to educate these populations about the importance of clinical research and to encourage greater diversity among clinical trial participants.

    Read Mo​​​re
  • March 14, 2014

    Clinical Drug Trials Aren’t Representative of America; This Group Wants to Change That

    Consider these numbers: According to Census data, Hispanics make up 16 percent of the entire population of the United States. In clinical trials, however, the Food and Drug Administration says they represent a mere 1 percent.

    Read Mo​​​re
  • March 13, 2014

    New Initiative Aims to Increase Diversity in Clinical Trials

    There is a severe underrepresentation of African Americans, Hispanics, and Asians in clinical trials, the processes pharmaceutical companies undertake to test and hone treatments for illnesses. Due to genetic differences between ethnic groups, diverse representation in clinical trials is vital to tailoring healthcare treatments for various demographics.

    Read Mo​​​re
  • March 12, 2014

    National Campaign launched to help increase diversity in Clinical Trials

    The Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Minority Quality Forum today announced a first-of-its-kind national campaign to help increase diversity in clinical trials.

    Read Mo​​​re
  • February​ 20, 2014​

    The Underlying Condition: Increasing Diversity in Clinical Trials

    Via National Journal:
    Opinion: African-Americans, at 12 percent of the population, comprise only 5 percent of clinical-trial participants; the numbers for Hispanics are 16 percent and 1 percent. It's time for that inequity to change, PhRMA's CEO says.

    Read Mo​​​re
  • February 11, 2014

    African American History Month: A Time for Reflections on Health Disparities

    Via HealthData.gov:
    ​February is Black History Month--an opportunity to reflect not only on our social and economic history, but also on the history of poor health status for America’s minority populations and the potential of using 21st century health information technology to assure optimal care for everyone.

    Read More
  • October 23, 2013

    A Discussion about Challenges and Opportunities in Pre-Competitive Partnerships, Clinical Trial Enrollment and Public Policy

    Alzheimer’s Disease (AD) is a debilitating neurodegenerative disease that currently afflicts more than 5 million people in the U.S. In an effort to catalyze progress in AD innovation and R&D, PhRMA, in partnership with the Alzheimer’s Association and the Alzheimer's Drug Discovery Foundation, is hosting an all-day forum to convene top industry and academic scientists, patients, policymakers, and other stakeholders.

    Read More
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

 Content Editor ‭[2]‬

Media Contact

For media information, please contact:
Emily Read
E-mail
(850) 224-0174

Download the Media Kit
​​​​​​